Apomorphine
Written and reviewed by Dr Ibrahim Imam, Consultant Neurologist. Last reviewed .
Apomorphine. It is a potent dopamine agonist. It improves off time in Parkinson’s disease (PD). Fully referenced neurology checklist.
Pharmacology
- It is a potent dopamine agonist
- It improves off time in Parkinson’s disease (PD)
- It has a similar efficacy to Levodopa
- It enables reduction of Levodopa dose
Indications
Locked: subscribe to see this section.
Continuous formulations
Locked: subscribe to see this section.
On demand formulations
Locked: subscribe to see this section.
Side effects
Locked: subscribe to see this section.
Precautions
Locked: subscribe to see this section.
Treatments for skin nodules
Locked: subscribe to see this section.
References
- Katzenschlager R, Poewe W, Rascol O, et al. Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial. Lancet Neurol 2018; 17:749-759.
- Gaire S, Kafle S, Bastakoti S, Paudel A, Karki K. Continuous subcutaneous apomorphine infusion in advanced Parkinson's disease: a systematic review. Cureus 2021; 13:e17949.
- Carbone F, Djamshidian A, Seppi K, Poewe W. Apomorphine for Parkinson's disease: efficacy and safety of current and new formulations. CNS Drugs 2019; 33:905-918.
- Lees A, Turner K. Apomorphine in Parkinson’s disease. Pract Neurol 2002; 2:280-287.
- Chen JJ, Obering C. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease. Clin Ther 2005; 27:1710-1724.
- And 4 more. Subscribe to see the full list
